Ciloxan Ophthalmic Solution for Effective Bacterial Conjunctivitis Treatment
Ciloxan Ophthalmic Solution
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 4 | $12.50 | $50.00 (0%) | 🛒 Add to cart |
| 5 | $11.40 | $62.50 $57.00 (9%) | 🛒 Add to cart |
| 6 | $10.50
Best per flacon | $75.00 $63.00 (16%) | 🛒 Add to cart |
Synonyms | |||
Ciloxan (ciprofloxacin hydrochloride ophthalmic solution) 0.3% is a sterile, antimicrobial topical solution formulated for the treatment of ocular infections caused by susceptible strains of microorganisms. As a fluoroquinolone antibiotic, it offers potent bactericidal activity through inhibition of bacterial DNA gyrase and topoisomerase IV. This prescription medication is indicated for corneal ulcers and bacterial conjunctivitis, providing targeted therapy with a well-established efficacy and safety profile. Proper diagnosis by a qualified healthcare professional is essential before initiation of treatment.
Features
- Contains 0.3% ciprofloxacin hydrochloride as the active pharmaceutical ingredient
- Preservative-free formulation in single-use containers available
- Sterile isotonic solution with pH approximately 4.5
- Compatible with ocular tissue with minimal irritation
- Stable at room temperature (15-30°C/59-86°F)
- Available in 2.5mL, 5mL, and 10mL dropper bottles
Benefits
- Rapid bactericidal action against gram-positive and gram-negative pathogens
- High corneal penetration for effective treatment of anterior segment infections
- Reduced risk of resistance development compared to earlier generation antibiotics
- Convenient dosing regimen that supports patient compliance
- Minimal systemic absorption when used as directed
- Proven clinical efficacy in numerous controlled studies
Common use
Ciloxan ophthalmic solution is primarily prescribed for the treatment of bacterial conjunctivitis caused by susceptible strains of Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens. It is also indicated for corneal ulcers caused by susceptible strains of Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and certain strains of Streptococcus. The solution may be used as prophylactic treatment following corneal abrasion or in preoperative preparation for ocular surgery when determined appropriate by the treating ophthalmologist.
Dosage and direction
For bacterial conjunctivitis: Instill 1-2 drops into the affected eye(s) every 2 hours while awake for the first 2 days, then 1-2 drops every 4 hours while awake for the next 5 days. For corneal ulcers: Instill 2 drops into the affected eye every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day. On day 2, instill 2 drops hourly while awake. On days 3 through 14, instill 2 drops every 4 hours while awake. Wash hands thoroughly before administration. Avoid touching the dropper tip to any surface to prevent contamination. If using other eye medications, allow at least 5 minutes between applications.
Precautions
Use under strict medical supervision only. Not for injection or oral use. Discontinue use and consult physician if rash or allergic reaction occurs. May cause temporary blurred vision after instillation—avoid driving or operating machinery until vision clears. Contact lenses should not be worn during treatment. Contains benzalkonium chloride as preservative in multi-dose formulations, which may be absorbed by soft contact lenses. Monitor for superinfection with nonsusceptible organisms with prolonged use. Use with caution in patients with history of hypersensitivity to other quinolones. Pregnancy Category C: Use only if potential benefit justifies potential risk to fetus.
Contraindications
Hypersensitivity to ciprofloxacin, other quinolone antimicrobial agents, or any component of this formulation. History of tendon disorders related to quinolone use. Not recommended for viral or fungal corneal ulcers. Contraindicated in patients with known resistance patterns to fluoroquinolones. Should not be used for trivial infections where safer alternatives are available.
Possible side effects
Most common: transient ocular burning, discomfort, or pain immediately after instillation (approximately 5-10% of patients); conjunctival hyperemia; foreign body sensation; itching; photophobia; corneal staining; blurred vision; bad taste following nasolacrimal duct drainage. Less common: eyelid edema, tearing, dryness, ocular itching, nausea, decreased vision, corneal infiltrates. Rare: allergic reactions, lid margin crusting, conjunctival hemorrhage, corneal edema, dizziness, headache, corneal ulceration, superinfection, corneal perforation (in severe ulcers). Discontinue use and seek medical attention if severe reactions occur.
Drug interaction
No formal drug interaction studies have been conducted with ophthalmic ciprofloxacin. However, systemic quinolones interact with theophylline, caffeine, warfarin, cyclosporine, and nonsteroidal anti-inflammatory drugs. Although systemic absorption is minimal, caution is advised when using concurrently with these medications. Avoid concomitant use with other ocular medications containing metallic cations (zinc, iron, calcium) which may chelate with ciprofloxacin and reduce efficacy. Separate administration by at least 15 minutes if multiple eye medications are required.
Missed dose
If a dose is missed, administer as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Maintain as consistent a dosing schedule as possible to ensure therapeutic antibiotic levels are maintained in the ocular tissues.
Overdose
Topical overdose is unlikely due to minimal systemic absorption. Excessive administration may be rinsed from the eye(s) with warm water. If accidentally ingested, seek medical attention immediately. Symptoms of oral overdose may include nausea, vomiting, diarrhea, headache, dizziness, and tremors. Treatment should be supportive with gastric lavage if ingestion occurred recently. Hemodialysis removes approximately 10% of systemically administered ciprofloxacin.
Storage
Store at controlled room temperature 15-30°C (59-86°F). Protect from light. Do not freeze. Keep container tightly closed when not in use. Discard any unused solution 4 weeks after opening the multi-dose bottle. Single-use containers should be discarded immediately after use. Keep out of reach of children and pets. Do not use if solution changes color or becomes cloudy.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment recommendations. The prescribing physician should be aware of the complete medical history of the patient before initiating therapy. Proper diagnosis of the infectious organism is essential for appropriate antimicrobial selection. Use only as directed by a healthcare provider.
Reviews
Clinical studies demonstrate Ciloxan’s efficacy with 85-92% clinical improvement rates in bacterial conjunctivitis patients within 5-7 days of treatment. Ophthalmologists report satisfactory results in corneal ulcer treatment with complete epithelialization achieved in most cases within 2 weeks. Patients note rapid symptom relief, though some report transient burning upon instillation. The convenient dosing schedule receives positive feedback regarding compliance compared to more frequent regimens. Microbial eradication rates exceed 90% for susceptible organisms in controlled trials.